Haizhi Technology Group (02706) surged more than 14% intraday before paring gains, with the stock last up 4.70% at HK$29.86 on turnover of HK$55.7628 million.
The company announced it recently entered into a strategic cooperation framework agreement with Jointown Pharmaceutical Group Co., Ltd. Under the agreement, the two parties will pursue strategic cooperation focused on the digital and intelligent transformation of the pharmaceutical distribution industry, including but not limited to leveraging the Atlas Graph Solution and Atlas AI Agent as carriers.
The planned strategic cooperation under the framework agreement is expected to achieve resource complementarity and coordinated development, helping drive the digital and intelligent transformation—namely AI-driven upgrading—of the pharmaceutical distribution sector.
Separately, Huatai Securities recently updated its forecast for Hang Seng Tech Index inclusion, and Haizhi Technology Group remains on the predicted inclusion list. The company's core revenue has surged on the back of its Atlas AI Agent revenue, laying a foundation for long-term development and positioning it as a potential candidate for index reshuffling amid the current market adjustment.
According to Haizhi Technology Group's interim results report, revenue from its core growth engine, the Atlas AI Agent business, reached RMB 115 million, soaring 135.6% year-on-year, forming a "dual-wheel drive" development pattern alongside its traditional Atlas Graph business. This validates the long-term prosperity of the "Graph + Controllable AI" industrial path and gives the company a solid foundation for growth within the growth category.
Comments